A Brain‐Targeting Curcumin Analog Inhibits Glioblastoma Progression Through THBS1/TGF‐β1/PI3K–AKT Axis Modulation: Evidence From Experimental and Bioinformatic Analyses
Journal of Cellular and Molecular Medicine · 2026-03 · 30 (5)
DOI: 10.1111/jcmm.71065 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 10.03.2026. Verfasst von Zijian Han und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), Suzhou, Jiangsu Province, China. Hauptthemen laut MEDLINE: Glioblastoma, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinases, Curcumin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glioblastoma (GBM) is the most aggressive primary brain tumour, associated with a dismal prognosis and an urgent need for innovative therapeutic strategies. To address this challenge, our group developed DMC‐GF, a novel brain‐targeted curcumin analog engineered to enhance blood–brain barrier permeability by blocking metabolic sites and improving GLUT1 recognition. Although its activity against glioma stem cells has been reported, the direct mechanisms by which DMC‐GF acts on GBM cells remain unclear. In this study, we systematically investigated the molecular actions of DMC‐GF using phenotypic assays, transcriptome sequencing, and bioinformatics analysis. DMC‐GF exerted dose‐dependent inhibitory effects on GBM cell proliferation, migration and invasion and concurrently promoted apoptosis, as reflected by reduced Bcl‐2 expression, activation of Bax/Caspase‐3 and reversal of epithelial–mesenchymal transition (E‐cadherin↑, N‐cadherin↓, MMP‐3↓). Transcriptomic profiling identified THBS1 as a key downstream target, showing marked suppression following DMC‐GF treatment. Functional experiments further confirmed that THBS1 knockdown mimics the anti‐tumour effects of DMC‐GF, whereas THBS1 overexpression partially mitigates its inhibitory actions. Mechanistic studies revealed that DMC‐GF suppresses the non‐canonical, Smad‐independent TGF‐β1 pathway by downregulating THBS1, thereby inhibiting PI3K/AKT signalling, as reflected by reduced phosphorylation of AKT, GSK3β and mTOR. Collectively, this work provides the first evidence that DMC‐GF exerts anti‐GBM effects through modulation of the THBS1/TGF‐β1/PI3K‐AKT axis. These findings suggest DMC‐GF as a compelling brain‐targeted therapeutic candidate, providing new mechanistic insights and a potential clinical strategy to overcome therapeutic resistance in GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), Suzhou, Jiangsu Province, China.
- Soochow Kowloon Hospital of Shanghai Jiao Tong University, Suzhou, Jiangsu Province, China.
ORCID-Profile: Zijian Han, Xuetao Li, Yang Zhu, Zhimin Wang, Yingbo Hou, Huiling Tao, Meng Ma, Xiangtong Xie, HaiYang Zhang
Zitieren
APA
Han, Z., Li, X., Zhu, Y., Wang, Z., Hou, Y., Tao, H., Ma, M., Xie, X., & Zhang, H. (2026). A Brain‐Targeting Curcumin Analog Inhibits Glioblastoma Progression Through THBS1/TGF‐β1/PI3K–AKT Axis Modulation: Evidence From Experimental and Bioinformatic Analyses. Journal of Cellular and Molecular Medicine, 30(5). https://doi.org/10.1111/jcmm.71065
Vancouver
Han Z, Li X, Zhu Y, Wang Z, Hou Y, Tao H, et al. A Brain‐Targeting Curcumin Analog Inhibits Glioblastoma Progression Through THBS1/TGF‐β1/PI3K–AKT Axis Modulation: Evidence From Experimental and Bioinformatic Analyses. Journal of Cellular and Molecular Medicine. 2026;30(5). doi:10.1111/jcmm.71065
BibTeX
@article{Han2026,
author = {Han, Zijian and Li, Xuetao and Zhu, Yang and Wang, Zhimin and Hou, Yingbo and Tao, Huiling and Ma, Meng and Xie, Xiangtong and Zhang, HaiYang},
title = {A Brain‐Targeting Curcumin Analog Inhibits Glioblastoma Progression Through THBS1/TGF‐β1/PI3K–AKT Axis Modulation: Evidence From Experimental and Bioinformatic Analyses},
journal = {Journal of Cellular and Molecular Medicine},
year = {2026},
volume = {30},
number = {5},
doi = {10.1111/jcmm.71065}
}
EUVIMED